JP2023545359A - 抗ｈｅｒ２抗体－薬物複合体治療のためのスコアリング方法 - Google Patents

抗ｈｅｒ２抗体－薬物複合体治療のためのスコアリング方法 Download PDF

Info

Publication number
JP2023545359A
JP2023545359A JP2023515569A JP2023515569A JP2023545359A JP 2023545359 A JP2023545359 A JP 2023545359A JP 2023515569 A JP2023515569 A JP 2023515569A JP 2023515569 A JP2023515569 A JP 2023515569A JP 2023545359 A JP2023545359 A JP 2023545359A
Authority
JP
Japan
Prior art keywords
cancer
adc
cell
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023515569A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023545359A5 (https=
Inventor
シュミット，ギュンター
ブリュー，ニコラス
スピッツミューラー，アンドレアス
カピル，アンシュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
AstraZeneca UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca UK Ltd filed Critical AstraZeneca UK Ltd
Publication of JP2023545359A publication Critical patent/JP2023545359A/ja
Publication of JP2023545359A5 publication Critical patent/JP2023545359A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V20/00—Scenes; Scene-specific elements
    • G06V20/60—Type of objects
    • G06V20/69—Microscopic objects, e.g. biological cells or cellular parts
    • G06V20/698—Matching; Classification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F18/00—Pattern recognition
    • G06F18/20—Analysing
    • G06F18/24—Classification techniques
    • G06F18/241—Classification techniques relating to the classification model, e.g. parametric or non-parametric approaches
    • G06F18/2413—Classification techniques relating to the classification model, e.g. parametric or non-parametric approaches based on distances to training or reference patterns
    • G06F18/24133—Distances to prototypes
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V10/00—Arrangements for image or video recognition or understanding
    • G06V10/40—Extraction of image or video features
    • G06V10/44—Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersections; Connectivity analysis, e.g. of connected components
    • G06V10/443—Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersections; Connectivity analysis, e.g. of connected components by matching or filtering
    • G06V10/449—Biologically inspired filters, e.g. difference of Gaussians [DoG] or Gabor filters
    • G06V10/451—Biologically inspired filters, e.g. difference of Gaussians [DoG] or Gabor filters with interaction between the filter responses, e.g. cortical complex cells
    • G06V10/454—Integrating the filters into a hierarchical structure, e.g. convolutional neural networks [CNN]
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V10/00—Arrangements for image or video recognition or understanding
    • G06V10/70—Arrangements for image or video recognition or understanding using pattern recognition or machine learning
    • G06V10/74—Image or video pattern matching; Proximity measures in feature spaces
    • G06V10/75—Organisation of the matching processes, e.g. simultaneous or sequential comparisons of image or video features; Coarse-fine approaches, e.g. multi-scale approaches; using context analysis; Selection of dictionaries
    • G06V10/751—Comparing pixel values or logical combinations thereof, or feature values having positional relevance, e.g. template matching
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V20/00—Scenes; Scene-specific elements
    • G06V20/60—Type of objects
    • G06V20/69—Microscopic objects, e.g. biological cells or cellular parts
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V2201/00—Indexing scheme relating to image or video recognition or understanding
    • G06V2201/03—Recognition of patterns in medical or anatomical images

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Theoretical Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Multimedia (AREA)
  • Evolutionary Computation (AREA)
  • Artificial Intelligence (AREA)
  • Medicinal Chemistry (AREA)
  • Data Mining & Analysis (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Software Systems (AREA)
  • Medical Informatics (AREA)
  • Databases & Information Systems (AREA)
  • Computing Systems (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
JP2023515569A 2020-09-12 2021-09-11 抗ｈｅｒ２抗体－薬物複合体治療のためのスコアリング方法 Pending JP2023545359A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063077604P 2020-09-12 2020-09-12
US63/077,604 2020-09-12
PCT/IB2021/058273 WO2022054009A2 (en) 2020-09-12 2021-09-11 A scoring method for an anti-her2 antibody-drug conjugate therapy

Publications (2)

Publication Number Publication Date
JP2023545359A true JP2023545359A (ja) 2023-10-30
JP2023545359A5 JP2023545359A5 (https=) 2024-09-11

Family

ID=77801755

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515569A Pending JP2023545359A (ja) 2020-09-12 2021-09-11 抗ｈｅｒ２抗体－薬物複合体治療のためのスコアリング方法

Country Status (10)

Country Link
US (1) US20240426826A1 (https=)
EP (1) EP4211598B1 (https=)
JP (1) JP2023545359A (https=)
KR (1) KR20230066094A (https=)
CN (1) CN116601713A (https=)
AU (2) AU2021340002B9 (https=)
CA (1) CA3195062A1 (https=)
ES (1) ES3064041T3 (https=)
IL (1) IL301265A (https=)
WO (1) WO2022054009A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240037740A1 (en) * 2022-07-28 2024-02-01 Applied Materials, Inc. Method and system for automatic ihc marker-her2 score
EP4623936A1 (en) * 2022-11-22 2025-10-01 Keymed Biosciences (Chengdu) Co., Ltd. Fused ring compound, conjugate thereof and use thereof
WO2025103192A1 (zh) * 2023-11-16 2025-05-22 上海齐鲁制药研究中心有限公司 一种氘代喜树碱化合物及其制备和应用
WO2025162211A1 (zh) * 2024-01-29 2025-08-07 正大天晴药业集团股份有限公司 抗her2抗体药物偶联物治疗胃癌的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019110583A1 (en) * 2017-12-07 2019-06-13 Ventana Medical Systems, Inc. Deep-learning systems and methods for joint cell and region classification in biological images
WO2020023213A1 (en) * 2018-07-27 2020-01-30 Ventana Medical Systems, Inc. Systems for automated in situ hybridization analysis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
EP2854851A4 (en) * 2012-06-01 2016-03-30 Momenta Pharmaceuticals Inc Methods related to trastuzumab
IL310627B2 (en) * 2014-01-31 2026-04-01 Daiichi Sankyo Co Ltd Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof
GB201502590D0 (en) * 2015-02-16 2015-04-01 Lonza Ag Method and apparatus for designing proteins
MX2017015260A (es) * 2015-06-03 2018-02-19 Squibb Bristol Myers Co Anticuerpos anti receptor de factor de necrosis tumoral inducible por glucocorticoide (gitr) para diagnostico del cancer.
CN110651189B (zh) * 2017-03-03 2024-10-25 特雷斯生物有限公司 肽疫苗
EP3659110A1 (en) * 2017-07-24 2020-06-03 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in tumor samples
EP3797296B1 (en) * 2018-05-21 2024-09-04 Genentech, Inc. Her2 heterogeneity as a biomarker in cancer
US11030744B2 (en) * 2018-06-26 2021-06-08 Astrazeneca Computational Pathology Gmbh Deep learning method for tumor cell scoring on cancer biopsies
WO2022162164A1 (en) * 2021-01-29 2022-08-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019110583A1 (en) * 2017-12-07 2019-06-13 Ventana Medical Systems, Inc. Deep-learning systems and methods for joint cell and region classification in biological images
WO2020023213A1 (en) * 2018-07-27 2020-01-30 Ventana Medical Systems, Inc. Systems for automated in situ hybridization analysis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRITISH JOURNAL OF CANCER, vol. 117, JPN6025042625, 2017, pages 1736 - 1742, ISSN: 0005711990 *
COMPUTERS IN BIOLOGY AND MEDICINE, vol. 110, JPN6025042623, 2019, pages 164 - 174, ISSN: 0005711988 *
J PHARMACOL EXP THER, vol. 374, JPN6025042624, July 2020 (2020-07-01), pages 184 - 199, ISSN: 0005711989 *

Also Published As

Publication number Publication date
IL301265A (en) 2023-05-01
AU2021340002B2 (en) 2024-06-20
EP4211598B1 (en) 2026-01-07
CA3195062A1 (en) 2022-03-17
AU2021340002A1 (en) 2023-05-25
US20240426826A1 (en) 2024-12-26
WO2022054009A2 (en) 2022-03-17
ES3064041T3 (en) 2026-04-22
EP4211598A2 (en) 2023-07-19
AU2024219803A1 (en) 2024-10-10
WO2022054009A3 (en) 2022-04-21
KR20230066094A (ko) 2023-05-12
CN116601713A (zh) 2023-08-15
AU2021340002B9 (en) 2024-09-12
AU2021340002A9 (en) 2024-08-01

Similar Documents

Publication Publication Date Title
EP4211598B1 (en) A scoring method for an anti-her2 antibody-drug conjugate therapy
CN116438199A (zh) 细胞定位特征和免疫疗法
US20230176060A1 (en) Tumour biomarkers for immunotherapy
JP2025509564A (ja) 抗ｔｒｏｐ２抗体－薬物コンジュゲート治療のためのスコアリング方法
US11169154B2 (en) Phosphocofilin: cofilin co-localization intensity as a predictor of metastatic recurrence
RU2706967C2 (ru) Антитело к igf-1r и его применение для диагностики рака
JP7829563B2 (ja) 抗ｂ７ｈ４抗体薬物コンジュゲート療法のためのスコア化方法
WO2010098435A1 (ja) 癌転移部位検出方法、検出用キットおよびこれらを用いる癌の治療方法
RU2706959C2 (ru) Антитело к igf-1r и его применение для диагностики рака
AU2019228339A1 (en) Progastrin as a biomarker for immunotherapy
WO2026052764A1 (en) A scoring method for an anti-trop2 antibody drug conjugate therapy
HK40099135A (zh) 用於抗b7h4抗体-药物缀合物疗法的评分方法

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20230808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240903

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251021

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260402